Cognizant’s digital expertise is solving some of today’s most pressing challenges for pharmaceutical, biotech and medical device companies. This is an introduction to how AI, robotics, automation, IoT and other technologies can improve productivity, enhance drug safety and ensure regulatory compliancy.
Explore how Cognizant helped a life sciences company achieve 30% reduction in end-to-end cycle time by automation of a highly manual process. The RPA solution was completed and went live in just seven months, and will now be leveraged in other parts of the organization.
We’re amidst a huge remaking of the life sciences industry, a change that pivots around five main technology trends: AI and automation, human augmentation, edge analytics/ processing, data ownership and protection, and the intermingling of products and services.
Cognizant is named one of the top providers of digital services for life sciences organizations in the 2018 PEAK Matrix report by research and consulting firm Everest Group. Previously, we’ve also been named a Digital Transformation Leader in the life science industry by advisory services firm IDC.
Life sciences organizations are increasingly working with global partners and service providers in extended networks. How does it affect regulatory compliance?
WHO believes that 80% of all visual impairment caused by DR can be cured with early detection. Cognizant developed an AI-based diagnostic tool to help doctors.
Cognizant has helped numerous organizations across industries to achieve benefits through RPA. Among them is a major postal services organization in the Nordics.
Artificial intelligence can rapidly accelerate and improve business processes by placing customer interaction at the heart of the digital operation.
Cognizant is redefining the way life sciences companies do digital. That’s why all 30 of the top 30 global pharmaceutical companies, 9 of the top 10 biotech companies and 12 of the top 15 medical device companies work with us.
